SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16483)11/23/2003 5:32:47 PM
From: Robert K.  Respond to of 17367
 
Blue, you read into my points quick enough. IMO 208 is only a target.
If results are positive anything might happen. You know what I want> a meningo submission. As Jack said> "now that we have bpi back ,believe me we are considering all possible options."
>>>>He is aware of my submit idea.<<<<
What is more likely that they get some "additional data" that is RELEVENT to meningo is SOME WAY from cpb or some other study. IT IS POSSIBLE. How likely is the question and that might be dependant on the compellingness of the data.
skd



To: Bluegreen who wrote (16483)11/23/2003 9:37:14 PM
From: aknahow  Read Replies (4) | Respond to of 17367
 
The combination of the FDA and Xoma refual to fight or say anything are discouraging. But you post is on target.

But I am happy doing what I am doing, and it would take a change of attitude in Xoma to get me buy back. Not a change in management, just the attitude that they don't have to say anything about anything.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News